Liraglutide, semaglutide, and tirzepatide are all GLP-1 agonists resulting in significant weight loss in RCTs
Together, these findings suggest broad experimental potential for CJC-1295 and Ipamorelin across multiple biological pathways
In practice, if you handled semaglutide well, there's a good chance you'll handle tirzepatide well, especially with the slow dose escalation
Thiamine (Vitamin B1) deserves special mention, particularly for patients experiencing persistent vomiting, which warrants urgent medical assessment
Continuous therapy allows you to maintain appetite control, weight stability, and metabolic benefits without interruption
7 Other studies have shown an association with GLP-1 RAs and lower obesity-related cancer risk, 8 and preliminary data suggest no increased recurrence risk and possible cardiovascular benefits